Zobrazeno 1 - 10 of 237 pro vyhledávání: '"Shepshelovich, D"'
1
Akademický článek
Reporting infections in clinical trials of patients with haematological malignancies
Autor: Tau, N., Shargian-Alon, L., Reich, S., Paul, M., Gafter-Gvili, A., Shepshelovich, D., Yahav, D.
Publikováno v: In Clinical Microbiology and Infection December 2019 25(12):1494-1500
Zobrazit plný text záznamu
3
The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis
Autor: Dabush, DR, Shepshelovich, D, Shochat, T, Tibau, A, Amir, E, Goldvaser, H
Publikováno v: CANCER TREATMENT REVIEWS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: The impact of interval of restaging on the observed magnitude of benefit of progression-free survival (PFS) is undefined. Materials and Methods: Phase 3 randomized controlled trials (RCTs) investigating anti-neoplastic drugs for metastati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::edca0c6adc3c545e4ac2c74862857443
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4253
Zobrazit plný text záznamu
4
National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study
Autor: Etan, T, Amir, E, Tibau, A, Yerushalmi, R, Moore, A, Shepshelovich, D, Goldvaser, H
Publikováno v: CANCER TREATMENT REVIEWS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Background: National Comprehensive Cancer Network (NCCN) guidelines can include recommendations for off label use of anti-cancer drugs. Here, we evaluate NCCN recommendations not supported by US Food and Drug Administration (FDA) approval and explore
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::9a2a15ba6d5683df2a109d8394d42fb3
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1262
Zobrazit plný text záznamu
5
Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies
Autor: Gafter-Gvili, A, Tibau, A, Raanani, P, Shepshelovich, D
Publikováno v: ACTA HAEMATOLOGICA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
The prevalence of safety-related postmarketing label modifications of medications for hematological malignancies is unknown. We identified 35 new drugs indicated for hematological malignancies approved by the US Food and Drug Administration between J
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3ee6b474d7e21405acaccced6d16b8b4
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2170
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Incidence of lung cancer following pneumonia in smokers: a population-based study.
Autor: Shepshelovich, D, Barda, N, Goldvaser, H, Dagan, N, Zer, A, Diker-Cohen, T, Balicer, R, Gafter-Gvili, A
Publikováno v: QJM: An International Journal of Medicine; May2022, Vol. 115 Issue 5, p287-291, 5p
Zobrazit plný text záznamu
8
Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials
Autor: Shepshelovich, D, Tibau, A, Goldvaser, H, Ocana, A, Seruga, B, Amir, E
Publikováno v: MAYO CLINIC PROCEEDINGS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Objective: To investigate whether US Food and Drug Administration approval of new drugs without randomization or an active drug comparator is associated with more postmarketing safety-related label modifications. Methods: We searched Drugs@FDA for ne
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::27204684d74ce3a1d2fd73e717ba9b4d
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3151
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje